Cytokine-induced killer cells in the treatment of patients with renal cell carcinoma: a pooled meta-analysis. (June 2014)

• Record Type: Journal Article
• Authors: Wang, Zheng-Xu; Li, Jun-Li; Cao, Jun-Xia; Liu, Yi-Shan; Li, Duo; Zhang, Xiao-Yan; Wang, Min; Wu, Min; Xu, Bei-Lei; Liu, Jin-Long; Wang, Hai-Bo
• Is Part Of: Immunotherapy. Volume 6:Number 6(2014:Jun.)
• Page Start: 787
• Page End: 795
• Publication Date: 2014-06
• Subjects: cytokine-induced killer cell -- immunotherapy -- meta-analysis -- renal cell carcinoma; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt.14.41
• Languages: English
• ISSNs: 1750-743X

Abstract

Cytokine-induced killer cells (CIKs) have been applied in multifarious cancer. Here, we address the connection between immune therapy and clinical responses by a systematic meta-analysis. A total of 385 patients (including 183 controls) were identified for renal cell cancer (RCC) in the seven selected trials. The estimated pooled complete response and partial response showed a significant improvement for patients receiving CIK immunotherapy compared with non-CIK therapy (p < 0.0001), which was up to 62% of clinical response. The overall analysis showed a significant survival benefit (1-year overall survival [OS]: p = 0.0002; 3-year OS: p < 0.0001) in favor of CIK-based therapy in RCC, thus a statistically significant effect of OS and clinical response was demonstrated in RCC patients.